No Picture
News

Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call

SAN DIEGO, Aug: SAN DIEGO, Aug, 3, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended June 30, 2021… Click here to view original post… […]

No Picture
News

Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-CoV-2 and Its Variants of Concerns

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its subsidiary company, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN (“Instituto National de Medicine Genomica”) to cooperate in the development,… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and cancer, announced today that the Company has signed a Binding Term Sheet to acquire the… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Rethinking Remdesivir

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe. Click here to view original post… […]

No Picture
News

Rethinking Remdesivir

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
[…]

No Picture
News

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the FDA has authorized Sorrento’s IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) – T Cell therapy for relapsed or refractory multiple myeloma. The… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif.: LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $100 million… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021. Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

CARLSBAD, Calif.: CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular… Click here to view original post… […]

No Picture
News

Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)

LA JOLLA, Calif.: LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ — Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Micronoma Wins Bio-IT World Innovative Practices Award

SAN DIEGO: SAN DIEGO, Aug. 2, 2021 /PRNewswire/ — Micronoma, the first cancer detection biotech company to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology, announces that they are the recipient of the Bio-IT World Innovative Practices Award. This elite awards program highlights outstanding examples of how… Click here to view original post… […]